Anthea Pharma Private Limited - Due diligence report

A 360° intelligence report on Anthea Pharma: trust score, financial health, credit view, compliance, directors, growth and distress signals …

2019-11-05 Hyderabad, Telangana Active Unlisted
Share
AP Anthea Pharma Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Anthea Pharma — 360° Intelligence Report

Generated from MCA filings & public records
76/100
Trust Score
Low Risk

Anthea Pharma is assessed as Low Risk with a Trust Score of 76/100. Anthea Pharma is an active private limited indian non-government company incorporated in 2019, operating in the Pharma sector. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and moderate financial risk profile.

Report generated on 16 Jul 2026 from the latest processed filings. Anthea Pharma Private Limited snapshot & full profile →

Financial Health › Good
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
76/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
80/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
60/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
35/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
70/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
65/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 35/100 Caution Indicated
  • Negative operating earnings - debt service depends on external support.
  • Open charges exceed net worth - secured lenders rank ahead.
  • Working-capital cover adequate.

Charges position: 4 open (800.48 cr) · 0 satisfied (-).

Banking relationships (from registered charges)
LenderChargesAmount
Canara Bank1 48.0 cr
Others3 48.0 cr
Compliance Score: 80/100 Low Risk
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2024).
  • Delayed payments to MSME suppliers disclosed (26 disclosure(s)).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
PAVAN KUMAR GORUKANTI 01234567 Director 01/04/2018 6 yrs Approved
ABHINAV GORUKANTI 01234567 Director 01/04/2018 6 yrs Approved
SUCHITA DUGAR 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2024 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Yashoda Healthcare Services Private Limited
Subsidiaries
-
Group entities
-
Capital events
17 allotment(s) · 15 transfer(s)

Promoters hold a majority stake - exact percentages are part of the full report.

Group entityRelationship% held
Yashoda Healthcare Services Private Limited Holding Company 74.00%

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 70 · Distress 65
Growth signals & trust indicators
Latest year revenue grew 38%.
Asset base grew 1.42 - capacity expansion.
EPFO headcount growing - hiring signal.
Operating for 6 years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Losses deepening year-on-year.
Outside liabilities up 2.1x in a year.
4 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 16.59 Lakh.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence74/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 2 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment54/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 4 open charge(s) of 800.48 cr already registered.
  • Compliance record supports lending.
Investor view68/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • 3 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
23 Oct 2024
Charge created
Others - 50.00 cr
Charge created
Others - 200.00 cr
27 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Share transfer (FY 2024)
17750000.00000000 shares to Ravender Rao Gorukanti
Share transfer (FY 2024)
17750000.00000000 shares to Surender Rao Gorukanti
Share transfer (FY 2024)
354995.00000000 shares to Pavan Kumar Gorukanti
Share transfer (FY 2024)
355005.00000000 shares to Abhinav Gorukanti
Share transfer (FY 2024)
50000000.00000000 shares to Ravender Rao Gorukanti
Share transfer (FY 2024)
50000000.00000000 shares to Surender Rao Gorukanti
Share transfer (FY 2024)
1000000.00000000 shares to Pavan kumar Gorukanti
Share transfer (FY 2024)
1000000.00000000 shares to Abhinav Gorukanti
Latest balance sheet
Filed with ROC
01 Aug 2023
Director appointed
SUCHITA DUGAR (Company Secretary)
31 Mar 2023
Share transfer (FY 2023)
2745000.00000000 shares to KUMAR PAVAN GORUKANTI
Share transfer (FY 2023)
49000000.00000000 shares to ABHINAV GORUKANTI
10

Key Observations

Auto-generated from the data above
Debt-to-equity stands at 24% - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
3 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a majority stake as per the FY 2024 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 17 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Kaps Three Nutra Private Limited U24304GJ2018PTC101633 Surendranagar, Gujarat, India
High Purity Laboratory Chemicals Private Limited U24100MH2010PTC206470 Mumbai, Maharashtra, India
Dwarkesh Pharmaceutical Pvt Ltd U24230GJ1995PTC027524 Ahmedabad, Gujarat, India
Yds Lifescience Private Limited U24290GJ2021PTC125112 Ahmedabad, Gujarat, India
Betamax Remedies Private Limited U24239CH1996PTC018058 Chandigarh, Chandigarh, India
Vetmin Nutrition Private Limited U24290GJ2022PTC134059 Anand, Gujarat, India
Pmc Paints Private Limited U24222GJ2004PTC044757 Surat, Gujarat, India
Cosme Dream International Private Limited U24100MP2020PTC052877 Indore, Madhya Pradesh, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Anthea Pharma before audits and certifications: compliance score 80/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Anthea Pharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 35/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 70/100, margin trends, ownership structure and peer set for Anthea Pharma - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 76/100, distress signals and MSME payment-delay disclosures - know whether Anthea Pharma pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Anthea Pharma - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Anthea Pharma an active company?

Anthea Pharma has MCA status “Active” with a compliance score of 80/100 (Low Risk).

Is Anthea Pharma financially healthy?

Anthea Pharma has a Financial Health Score of 60/100 (Moderate) based on its filed financial statements.

Should I do business with Anthea Pharma?

Its overall Trust Score is 76/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Anthea Pharma?

The ultimate holding entity is Yashoda Healthcare Services Private Limited. 3 active director(s) are on record.

Does Anthea Pharma have loans or charges against its assets?

4 open charge(s) are registered against its assets.

Is Anthea Pharma up to date with its ROC filings?

Balance sheet slightly behind (Mar 2024). Overall compliance score: 80/100 (Low Risk).

Is it risky to lend to Anthea Pharma?

Its Credit Risk Score is 35/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.